Elevance Health, Inc. (ELV) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report on Form 10-Q for Elevance Health, Inc. for the period ended June 30, 2026. Elevance is a major U.S. health insurer serving approximately 44.9 million medical members through its Health Benefits, CarelonRx, and Carelon Services segments. The company operates as a Blue Cross and Blue Shield licensee in multiple states and serves the federal government through the Federal Employee Program.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | 2026 (YTD) | 2025 (YTD) | Change |
|---|---|---|---|
| Total Operating Revenue | $99,320 million | $98,186 million | +1.2% |
| Shareholders' Net Income | $3,227 million | $3,926 million | -17.8% |
| Diluted EPS | $14.73 | $17.33 | -15.0% |
| Operating Cash Flow | $6,245 million | $3,071 million | +103.4% |
| Total Assets | $126,438 million | $121,494 million | +4.1% |
| Total Debt (Long-term + Current) | $31,044 million | $32,995 million | -5.9% |
| Cash & Cash Equivalents | $10,232 million | $9,491 million | +7.8% |
| Debt-to-Capital Ratio | 40.8% | 42.1% | -130 bps |
Note: Debt figures include current portion of long-term debt ($375M) and long-term debt ($30,669M). Short-term borrowings were $0 at June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 1.2% year-over-year, driven by premium rate increases in the Health Benefits segment and growth in CarelonRx product revenues, partially offset by membership attrition.
- Profitability Decline: Net income decreased 17.8% primarily due to a $935 million loss contingency accrual related to the resubmission of historical Medicare Advantage risk adjustment data and higher medical costs in the Health Benefits segment.
- Membership Trends: Total medical membership declined 1.5% to 44.9 million. Significant decreases occurred in Medicare Advantage (-15.9%) and Medicaid (-4.3%) due to eligibility redeterminations, partially offset by growth in Employer Group Fee-Based business (+1.7%).
- Expense Ratios: The benefit expense ratio increased to 88.3% (from 87.7%) due to elevated medical cost trends in Medicaid and Medicare. The operating expense ratio rose to 12.0% (from 10.5%) due to the regulatory accrual and transformation program costs.
- Investment Performance: Net investment income increased 36.5% to $1,469 million, while net losses on financial instruments improved significantly (decreased by 77.5%) due to lower impairments.
Guidance, Outlook, and Risks
- Regulatory Resolution: On July 13, 2026, CMS confirmed that Elevance completed all required steps regarding the Medicare Advantage risk adjustment data submission, and sanctions will not be imposed. However, a remaining accrual of $593 million stands as of June 30, 2026.
- Transformation Program: The company is executing a 2026-2027 Operating Model Transformation Program to streamline operations and adopt AI. Costs incurred in the first six months were $129 million, with cash outlays expected through 2028.
- Capital Allocation: The company repurchased $1,358 million of common stock and paid $749 million in dividends during the period. Approximately $5,337 million remains authorized for future stock repurchases.
- Risk Factors: Key risks include elevated medical cost trends, regulatory changes (including the "One Big Beautiful Bill Act" and pharmacy benefit manager reforms), and ongoing litigation regarding antitrust and Medicare risk adjustment.
Investor Verification Checklist
- Regulatory Accrual Accuracy: Verify the remaining $593 million liability related to the CMS risk adjustment matter and the potential range of exposure ($320 million variance).
- Medical Cost Trends: Monitor the sustainability of the elevated benefit expense ratio (88.3%) and the impact of Medicaid redeterminations on future morbidity and costs.
- Membership Mix: Assess the long-term impact of the 15.9% decline in Medicare Advantage membership on future revenue stability.
- Transformation ROI: Track the progress and cost efficiency of the Operating Model Transformation Program against projected savings.
- Investment Portfolio: Review the composition of fixed maturity securities and the impact of interest rate fluctuations on unrealized gains/losses.